Literature DB >> 19476510

Following TRAIL's path in the immune system.

Christina Falschlehner1, Uta Schaefer, Henning Walczak.   

Abstract

The members of the tumour necrosis factor (TNF) superfamily of cytokines play important roles in the regulation of various immune-cell functions. Likewise, induction of cell death by apoptosis is indispensable for the normal functioning of the immune system. There are two major pathways of apoptosis induction. The intrinsic, or mitochondrial, pathway is regulated by the activation and interaction of members of the Bcl-2 family. The extrinsic, or death receptor, pathway is triggered by certain TNF family members when they engage their respective cognate receptors on the surface of the target cell. Hence, cell-to-cell-mediated death signals are induced by activation of these death receptor-ligand systems. Besides TNF itself and the CD95 (Fas/APO-1) ligand (FasL/Apo1L), the TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) belongs to the subfamily of ligands that is responsible for extrinsic induction of cell death. Depending on their status of stimulation, TRAIL can be expressed by various cells of the immune system, amongst them natural killer (NK) cells, T cells, natural killer T cells (NKT cells), dendritic cells and macrophages. TRAIL has been implicated in immunosuppressive, immunoregulatory and immune-effector functions. With respect to pathological challenges, TRAIL and its receptors have been shown to play important roles in the immune response to viral infections and in immune surveillance of tumours and metastases. In this review we summarize the current knowledge on the role of TRAIL and its receptors in the immune system and, based on this, we discuss future directions of research into the diverse functions of this fascinating receptor-ligand system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19476510      PMCID: PMC2691779          DOI: 10.1111/j.1365-2567.2009.03058.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  93 in total

1.  CD8+ T cells clear influenza virus by perforin or Fas-dependent processes.

Authors:  D J Topham; R A Tripp; P C Doherty
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

2.  Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Authors:  H Walczak; R E Miller; K Ariail; B Gliniak; T S Griffith; M Kubin; W Chin; J Jones; A Woodward; T Le; C Smith; P Smolak; R G Goodwin; C T Rauch; J C Schuh; D H Lynch
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

3.  TRAIL/Apo-2-ligand-induced apoptosis in human T cells.

Authors:  I Jeremias; I Herr; T Boehler; K M Debatin
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

4.  IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.

Authors:  L M Sedger; D M Shows; R A Blanton; J J Peschon; R G Goodwin; D Cosman; S R Wiley
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

5.  Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.

Authors:  G S Wu; T F Burns; Y Zhan; E S Alnemri; W S El-Deiry
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

6.  Characterization of the cytotoxic factor(s) released from thymic dendritic cells upon human immunodeficiency virus type 1 infection.

Authors:  S Beaulieu; M Lafontaine; M Richer; I Courchesne; E A Cohen; D Bergeron
Journal:  Virology       Date:  1998-02-15       Impact factor: 3.616

7.  Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity.

Authors:  N Kayagaki; N Yamaguchi; M Nakayama; A Kawasaki; H Akiba; K Okumura; H Yagita
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

8.  Safety and antitumor activity of recombinant soluble Apo2 ligand.

Authors:  A Ashkenazi; R C Pai; S Fong; S Leung; D A Lawrence; S A Marsters; C Blackie; L Chang; A E McMurtrey; A Hebert; L DeForge; I L Koumenis; D Lewis; L Harris; J Bussiere; H Koeppen; Z Shahrokh; R H Schwall
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

9.  Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs.

Authors:  N Kayagaki; N Yamaguchi; M Nakayama; H Eto; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

10.  Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

Authors:  T S Griffith; S R Wiley; M Z Kubin; L M Sedger; C R Maliszewski; N A Fanger
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

View more
  119 in total

Review 1.  Therapeutic molecular targets in human chondrosarcoma.

Authors:  Nuor Jamil; Sarah Howie; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

2.  TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Authors:  Mitsuhiro Iyori; Tong Zhang; Haddon Pantel; Bethany A Gagne; Charles L Sentman
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

Review 3.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

4.  Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function.

Authors:  You-Take Oh; Guoqing Qian; Jiusheng Deng; Shi-Yong Sun
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

5.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

6.  Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition.

Authors:  Weilong Yao; You-Take Oh; Jiusheng Deng; Ping Yue; Liang Deng; Henry Huang; Wei Zhou; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2016-08-30       Impact factor: 5.157

Review 7.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

8.  The LARGE principle of cellular reprogramming: lost, acquired and retained gene expression in foreskin and amniotic fluid-derived human iPS cells.

Authors:  Katharina Wolfrum; Ying Wang; Alessandro Prigione; Karl Sperling; Hans Lehrach; James Adjaye
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Innate immune function in placenta and cord blood of hepatitis C--seropositive mother-infant dyads.

Authors:  Christine Waasdorp Hurtado; Lucy Golden-Mason; Megan Brocato; Mona Krull; Michael R Narkewicz; Hugo R Rosen
Journal:  PLoS One       Date:  2010-08-30       Impact factor: 3.240

10.  Type I interferon induction is detrimental during infection with the Whipple's disease bacterium, Tropheryma whipplei.

Authors:  Khatoun Al Moussawi; Eric Ghigo; Ulrich Kalinke; Lena Alexopoulou; Jean-Louis Mege; Benoit Desnues
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.